Press Releases

First Biologics License Application (BLA) Submission on Track in August 2022 SAN CARLOS, Calif. , Aug. 04, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor infiltrating lymphocyte,

SAN CARLOS, Calif. , July 27, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its second quarter financial results on Thursday, August 4, 2022 .

SAN CARLOS, Calif. , July 22, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that on July 21, 2022 (the “Date of Grant”), the Company approved the grant of inducement

SAN CARLOS, Calif. , June 17, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that on June 16, 2022 (the “Date of Grant”), the Company approved the grant of inducement

SAN CARLOS, Calif. , June 13, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte, PBL), today announced the appointment of

SAN CARLOS, Calif. , June 08, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that senior leadership plans to present at the following conferences in June: Jefferies

Positive Results in Advanced Melanoma Patients, Including a 29% Objective Response Rate (ORR) in Cohort 4 of the C-144-01 Study Biologics License Application (BLA) Submission Planned for August 2022 Conference Call and Webcast Today at 5:00 p.m. ET SAN CARLOS, Calif.

SAN CARLOS, Calif. , May 20, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that on May 19, 2022 (the “Date of Grant”), the Company approved the grant of inducement stock

First Biologics License Application (BLA) Submission Planned in August 2022 SAN CARLOS, Calif. , May 05, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor infiltrating lymphocyte,

SAN CARLOS, Calif. , April 27, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that translational data for lifileucel in patients with metastatic melanoma will be

SAN CARLOS, Calif. , April 26, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its first quarter financial results on Thursday, May 5, 2022 .

SAN CARLOS, Calif. , April 25, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that senior leadership plans to present at the following conference: Chardan Genetic

SAN CARLOS, Calif. , April 22, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that on April 21, 2022 (the “Date of Grant”), the Company approved the grant of inducement

Positive FDA Feedback on Potency Assay Matrix to Support BLA Submission Further Defines Frontline Melanoma Strategy for Lifileucel in Combination with Pembrolizumab SAN CARLOS, Calif. , April 05, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology

SAN CARLOS, Calif. , March 16, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that senior leadership plans to present at the following conferences in March: Oppenheimer

SAN CARLOS, Calif. , March 15, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that on March 14, 2022 (the “Date of Grant”), the Company approved the grant of inducement

Clinical Study Expected to Begin in 2022 to Investigate the Safety and Efficacy of IOV-4001  to Deliver TIL and PD-1 Inhibition within a Single Cancer Therapy First Genetically Modified Iovance TIL Therapy Leverages TALEN® technology Licensed  from Cellectis to Inactivate PD-1 Expression SAN

SAN CARLOS, Calif. , March 08, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced the acceptance of two abstracts for presentation at the upcoming American Association for

Expanding TIL Platform in Multiple Solid Tumors and Treatment Settings SAN CARLOS, Calif. , Feb. 24, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor infiltrating lymphocyte, TIL,

SAN CARLOS, Calif. , Feb. 18, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that on February 17, 2022 (the “Date of Grant”), the Company approved the grant of inducement

SAN CARLOS, Calif. , Feb. 11, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its fourth quarter and full year financial results on Thursday, February 24, 2022 .

SAN CARLOS, Calif. , Jan. 21, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that on January 21, 2022 (the “Date of Grant”), the Company approved the grant of inducement

SAN CARLOS, Calif. , Jan. 10, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that Raj K. Puri , M.D., Ph.D., will join the Company as Executive Vice President, Regulatory

TIL Therapy was Successfully and Consistently Manufactured from Cryopreserved Tumor Samples Shipped from Australia   Local Cryopreservation of Tumor Samples may Address Challenges of Longer Shipment Times and Broaden Global Access for TIL Therapy SAN CARLOS, Calif. , Jan.

SAN CARLOS, Calif. , Jan. 06, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that Fred Vogt , PhD, Esq., Interim Chief Executive Officer, President and General Counsel of